Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers-Reference-Cited by-同舟云学术

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

Published:2018-10-30 Issue:1 Volume:144 Page:178-189
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mondal Susmita¹²,Roy Debarshi¹^ORCID,Sarkar Bhattacharya Sayantani¹,Jin Ling¹,Jung Deokbeom¹,Zhang Song³,Kalogera Eleftheria⁴,Staub Julie¹,Wang Yaxian¹,Xuyang Wen¹,Khurana Ashwani¹,Chien Jeremey⁵^ORCID,Telang Sucheta⁶,Chesney Jason⁶,Tapolsky Gilles⁷,Petras Dzeja³,Shridhar Viji¹

Affiliation:

1. Department of Experimental Pathology; Mayo Clinic; Rochester MN

2. Department of Microbiology; Sammilani Mahavidyalaya; Kolkata India

3. Division of Cardiovascular disease, Department of Medicine; Mayo Clinic; Rochester MN

4. Division of Gynecologic Surgery, Department of Obstetrics and Gynecology; Mayo Clinic; Rochester MN

5. Division of Molecular Medicine; University of New Mexico School of Medicine; Albuquerque NM

6. Department of Medicine; University of Louisville; Louisville KY

7. Advanced Cancer Therapeutics; Louisville KY

Funder

Mayo Clinic

National Institutes of Health

Publisher